ArticleJournal of pharmacy & bioallied sciences2025
Prevalence of Trismus and its Effects on Quality of Life in Patients Treated for Oral Squamous Cell Carcinoma: A Prospective Study.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trismus, a common complication of oral squamous cell carcinoma (OSCC) treatment, can significantly affect patients' quality of life (QoL). Understanding its prevalence and impact is crucial for improving patient care. Objective: To evaluate the prevalence of trismus and its effects on QoL in patients undergoing treatment for OSCC. Materials and Methods: This prospective research involved 150 OSCC patients undergoing surgery, radiotherapy, or combined therapy. Trismus was defined as maximum interincisal opening (MIO) ≤35 mm, measured at baseline, 3, and 6 months post-treatment. QoL was estimated using the EORTC QLQ-C30 and QLQ-H and N35 questionnaires. Results: Trismus prevalence was 28% at baseline, increasing to 55% at 3 months and 47% at 6 months. Patients with trismus had significantly lower QoL scores in domains such as pain, emotional well-being, and social interactions. Conclusion: Trismus is highly prevalent in OSCC patients and profoundly impacts QoL, highlighting the need for early interventions and targeted rehabilitation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.